MedTrace Logo

A Study to Evaluate TOUR006 in Patients With Chronic Kidney Disease and Elevated Hs-CRP

NCT06362759 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 143

Last updated 2026-02-24

No results posted yet for this study

Summary

This study will evaluate the safety, tolerability, pharmacokinetics, and CRP-lowering effect of quarterly and monthly subcutaneous administration of TOUR006 (also known as pacibekitug) in participants with chronic kidney disease and elevated hs-CRP.

Conditions

  • Chronic Kidney Diseases
  • Chronic Kidney Insufficiency
  • Chronic Renal Diseases
  • Chronic Renal Insufficiency
  • Kidney Insufficiency, Chronic
  • C-Reactive Protein
  • High Sensitivity C-Reactive Protein
  • Hs-CRP
  • hsCRP

Interventions

DRUG

TOUR006 - 50 MG

TOUR006 50 MG

DRUG

TOUR006 - 25 MG

TOUR006 25 MG

DRUG

TOUR006 - 15 MG

TOUR006 15 MG

OTHER

Placebo

Placebo

Sponsors & Collaborators

  • Tourmaline Bio, Inc.

    lead INDUSTRY

Principal Investigators

  • Clinical Trials · Tourmaline Bio

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-05-15
Primary Completion
2025-03-06
Completion
2025-12-04
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06362759 on ClinicalTrials.gov